People usually search for this
CJC-1295 (No DAC)/Ipamorelin Blend 5+5mg
$100.00
Products will arrive in a lyophilized (powder) form for maximum stability
This blend pairs a GHRH analog (CJC-1295 No-DAC / Mod GRF 1-29) with a selective GHRP (Ipamorelin), combining two complementary GH-release pathways. The No-DAC variant preserves natural pulsatile GH dynamics, while Ipamorelin's selectivity minimizes effects on cortisol and prolactin. Supplied as a 5mg + 5mg co-lyophilized vial at ≥99% HPLC purity per component, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
CJC-1295 (no DAC) + Ipamorelin
SYNONYMS
CJC-1295 (tetrasubstituted GHRH analog, no DAC), Ipamorelin (GHRP-2 analog)
CAS NUMBER
CJC-1295 (no DAC): 863288-34-0 Ipamorelin: 170851-70-4
MOLECULAR FORMULA
CJC-1295 (no DAC): C152H252N44O42 Ipamorelin: C38H49N9O5
MOLECULAR WEIGHT
CJC-1295 (no DAC): 3367.88 g/mol Ipamorelin: 711.86 g/mol
STRUCTURE
CJC-1295: Synthetic tetrapeptide; Ipamorelin: synthetic pentapeptide
PEPTIDE SEQUENCE
CJC-1295 (no DAC): H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
CHEMICAL STRUCTURE
CJC-1295: Ipamorelin:
CHEMICAL STRUCTURE
- CJC-1295 (no DAC): C152H252N44O42
- Ipamorelin: C38H49N9O5
Mechanism of Action
The CJC-1295 (no DAC) + ipamorelin peptide blend stimulates endogenous growth hormone (GH) release by simultaneously activating the growth hormone-releasing hormone receptor (GHRH-R) and the ghrelin/growth hormone secretagogue receptor (GHSR), resulting in synergistic, physiologically pulsatile GH secretion. This dual-receptor activation enhances circulating IGF-1 levels and supports anabolic and metabolic processes1-5.
Biological Activity
The CJC-1295 (no DAC) + ipamorelin blend increases circulating growth hormone and IGF-1 levels, promoting anabolic effects, tissue repair, lipolysis, and improved metabolic regulation in research models. This combination mimics natural GH pulsatility while minimizing off-target hormonal activity1-5.
Storage
- Store at -20°C, protect from light.
Drug Categories
GH secretagogues, GHRH analogs, GHSR agonists, research peptides
Additional Notes
For investigational use in laboratory settings only.
Summary Table
Property
Description
CAS Number
863288-34-0 (CJC-1295 no DAC), 170851-70-4 (ipamorelin)
Molecular Formula
C152H252N44O42; C38H49N9O5
Molecular Weight (MW)
3367.88 g/mol; 711.86 g/mol
Mechanism of Action
Dual GHRH-R and GHSR agonism; synergistic GH release
Biological Activity
Increases GH/IGF-1, supports tissue repair, lipolysis, metabolic regulation
Supplied Form
Lyophilized powder
Purity
≥99% (HPLC)
Storage
–20°C (lyophilized); 2–8°C (reconstituted, ?14 days)
Drug Categories
GH secretagogues, GHRH analogs, GHSR agonists, research peptides
Additional Notes
For research use only.
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
The CJC-1295 (no DAC) + Ipamorelin peptide blend is a dual-action investigational formulation developed to study endogenous GH axis modulation. CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH) that activates GHRH receptors in the pituitary, triggering robust and sustained GH secretion via the cAMP/PKA pathway. Ipamorelin (no DAC), a selective ghrelin receptor (GHS-R1a) agonist, induces GH release through calcium-dependent mechanisms without affecting prolactin or cortisol, offering a clean, receptor-specific action profile. Together, these peptides engage distinct but complementary mechanisms to mimic natural GH pulsatility. CJC-1295 initiates a broad GH release, and Ipamorelin (no DAC) enhances and extends this effect by acting on separate signaling pathways. The synergistic stimulation results in increased IGF-1 levels and prolonged anabolic signaling, promoting protein synthesis, lean muscle development, and recovery in research models.
Research Highlights
No peer-reviewed studies published as of June 2025. Information developed based on pharmacology of the individual peptides.
Synergistic Dual-Receptor Activation
- Combined stimulation of GHRH and GHS-R1a receptors leads to amplified and sustained GH release, mimicking natural physiologic pulsatility more effectively than monotherapy. This combination increases both the amplitude and duration of GH secretion, maximizing downstream IGF-1 production and anabolic effects.
- CJC-1295 (no DAC) binds GHRH receptors on pituitary somatotrophs, initiating GH secretion through the cAMP/PKA signaling cascade2.
- Ipamorelin selectively targets GHS-R1a, promoting GH release via calcium-mediated pathways1-5.
Mechanistic Synergy
- Sequential and complementary action: CJC-1295 initiates GH secretion; Ipamorelin prolongs and enhances it.
- Increased IGF-1 levels: Co-administration promotes higher systemic IGF-1, improving muscle protein synthesis, recovery, and lipolysis.
- Preserves natural feedback loops: The physiological stimulation allows for endogenous regulation without suppressing the pituitary axis.
- Reduced desensitization risk: Alternating receptor pathways mitigates receptor fatigue or downregulation seen in monotherapy1-5.
Pharmacokinetic Profile
Route of Administration
Subcutaneous
- Route of Administration: Subcutaneous Injection
Formulation & Handling
- Supplied as a sterile, lyophilized powder
- Reconstitute with sterile water or buffer as per laboratory protocol
- Store lyophilized at -20°C; reconstituted at 2-8°C for up to 14 days
Selected Clinical Trial Activity
CJC-1295 (No DAC) + Ipamorelin is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. CJC-1295 (No DAC) + Ipamorelin is supplied strictly for laboratory research and investigational purposes only.
References
1
Teichman, S. L. et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J. Clin. Endocrinol. Metab. 91, 799–805 (2006).
2
Raun, K. et al. Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. 139, 552–561 (1998).
3
Svensson, J. et al. Ipamorelin, a new growth hormone releasing peptide, induces muscle growth by stimulating GH release in rats. Am. J. Physiol. Endocrinol. Metab. 275, E123–E129 (1998).
4
Ghigo, E., Arvat, E., Muccioli, G. & Camanni, F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 136, 445–460 (1997).
5
Smith, R. G. et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 18, 621–645 (1997).
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
BPC-157 5mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157/TB-500/GHK-Cu 10+10+50mg (GLOW blend 70mg)
Summary Description: The GLOW Peptide Blend is a synthetic combination of three well-characterized regenerative peptides: BPC-157, TB-500, and GHK-Cu, each with complementary mechanisms that promote cellular repair, angiogenesis, and tissue remodeling. The blend integrates the nitric oxide-mediated cytoprotective activity of BPC-157, the actin-regulating and pro-angiogenic functions of TB-500, and the copper-mediated antioxidant and anti-fibrotic properties of GHK-Cu. Collectively, this tri-peptide formulation provides a multifaceted approach to studying regeneration, inflammation resolution, and extracellular matrix restoration in preclinical models
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 5mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
NAD+ 500mg
Summary Description: Nicotinamide adenine dinucleotide (NAD?) is a ubiquitous pyridine nucleotide coenzyme present in all living cells. It serves critical roles in cellular redox reactions for energy metabolism and acts as an essential substrate for key signaling enzymes regulating DNA repair, gene expression, and cell signaling. Cellular NAD? levels influence metabolic health, stress response, and tissue regeneration1,3.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 10mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
TB-500 10mg
Summary Description: TB-500 is a synthetic heptapeptide analog of the actin-binding motif of thymosin ?4 (T?4), composed of the acetylated sequence Ac-LKKTETQ. This fragment conserves the principal bioactive domain associated with T?4’s regenerative activity. TB-500 has been shown to promote cell migration, angiogenesis, cytoskeletal reorganization, and anti-inflammatory signaling in preclinical models1,2. Due to its shorter sequence, TB-500 offers enhanced metabolic stability and amenability to synthetic optimization compared to the parent protein. While TB-500 is banned in competitive sports, it continues to be studied for its potential in promoting angiogenesis, tissue repair, and modulation of actin-binding proteins.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 10mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability